Enlivex Ltd. (ENLV) stock
Close on Nov 13, 2026Market cap $20.03MP/E 0.0Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $20.03M
- P/E ratio
- 0.0
- Price to sales
- –
- Price to book
- 0.01
- Dividend yield
- –
- Free cash flow yield
- -52.34%
Fundamentals
- Net income
- $1.24B
- EPS, diluted
- $382.20
- Free cash flow
- -$10.48M
- Book value per share
- $201.63
- Diluted shares
- 19M
Trading
- Previous close
- $1.25
- Open
- $1.30
- Day's range
- $1.18 – $1.31
- Volume
- 22,312
- Average volume (20 days)
- 74,734
- 52-week range
- $0.19 – $434.38
- RSI (14 days)
- 43.5
- Volatility (1 year)
- 7741.1%
- Relative volume
- 0.04×
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ENLV | S&P 500 | Difference | ENLV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +435.1% | -3.0% | +438.1 pts | ||
| 3 months | -95.6% | -2.8% | −92.8 pts | ||
| Year to date | -88.7% | +11.5% | −100.2 pts | ||
| 1 year | -99.5% | +13.5% | −113.0 pts | ||
| 3 years | -99.7% | +77.7% | −177.4 pts | -85.8% | +21.1% |
| 5 years | -99.9% | +72.6% | −172.5 pts | -77.3% | +11.5% |
| 10 years | -99.9% | +308.2% | −408.1 pts | -52.0% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Enlivex filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Enlivex
Finance Services
Enlivex Ltd. is a clinical-stage immunotherapy company engaged in advancing therapies aimed at extending health span and quality of life. The company operates a dual model encompassing quality longevity therapeutics alongside a corporate treasury strategy focused on decentralized prediction markets infrastructure. Its principal product candidate is Allocetra, an off-the-shelf, universal cell therapy designed to restore macrophage homeostasis and rebalance the immune system to treat multiple inflammatory conditions, with a primary clinical indication in osteoarthritis. Potential recipients and target beneficiaries of the company's therapeutic candidates include patients suffering from debilitating and life-threatening conditions characterized by severe unmet medical needs.
Company profile, executives and historyEnlivex stock: common questions
What is Enlivex's stock price?
ENLV closed at $1.19 on Nov 13, 2026, down 4.42% on the day. Over the past 52 weeks it traded between $0.19 and $434.38.
What is Enlivex's market cap?
Enlivex was worth $20.03M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ENLV's P/E ratio?
ENLV trades at 0.0 times earnings, based on diluted earnings per share of $382.20 over fiscal 2025.
Does Enlivex pay a dividend?
No. Enlivex has not paid a cash dividend over the last twelve months.
How has ENLV stock performed over the past year?
Including dividends, ENLV returned -99.5% over the past year, against +13.5% for the S&P 500.
How many ENLV shares are sold short?
0M shares were sold short at the latest FINRA report, 0.25% of the float, or 1.0 days of average trading volume.
Who are Enlivex's competitors?
Companies most similar to Enlivex by business, industry and size include LITS, CNTN, BNBX, TAOX, ZSQR.
See a number that looks wrong?